Comparison of effects of aliskiren-based combination therapy between CCB and ARB in hypertensive patients with chronic kidney disease.

Trial Profile

Comparison of effects of aliskiren-based combination therapy between CCB and ARB in hypertensive patients with chronic kidney disease.

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 12 May 2016

At a glance

  • Drugs Aliskiren (Primary) ; Amlodipine; Valsartan
  • Indications Hypertension
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 04 Jul 2012 Status changed from recruiting to discontinued as reported by University Hospital Medical Information Network - Japan record.
    • 03 Dec 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top